Scott Kathleen D.'s Form 4 filing
ARS Pharmaceuticals, Inc. (SPRY) · filed Dec 1, 2022
- Accession no.
- 0001209191-22-059187
- Filed
- Dec 1, 2022
- Trade date
- Nov 29, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $51.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Scott Kathleen D.CIK 0001794284 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 29, 2022 | Common Stock | PPurchaseAcquired | +8,250 | $6.24F1 | +$51,480 | 8,250 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is the weighted average price. The shares were sold in multiple transactions at prices ranging from $6.16 to $6.26, inclusive. Upon request by the Securities and Exchange Commission staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
Referenced by the price of 1 transaction in Table I.